Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the ...

It is one of three major Novartis products that are nearing the end of their patent lives, along with cancer drug Tasigna (nilotinib) and Promacta (eltrombopag) for thrombocytopaenia, which ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA ...

Novartis's product lineup is anchored by several key growth drivers, including Cosentyx, Pluvicto, Kisqali, and Scemblix. These products are expected to play a crucial role in achieving the ...

Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines ...

Basel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting (AGM). A total of 1,693 ...

Basel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Phase III data demonstrated clinically meaningful 35.1% proteinuria reduction 6; also, a stabilization of estimated glomerular filtration rate (eGFR) – a key measure of kidney function – was observed ...

The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved ...